SCHEMBL8958672

SCHEMBL8958672

ON1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTAFR P25105 3/20 0.75
HRH1 P35367 12/20 0.74
SLC6A15 Q9H2J7 5/20 0.74
FNTA P49354 3/20 0.74
FNTB P49356 3/20 0.74
MEN1 O00255 1/20 0.70
LMNA P02545 1/20 0.70
ADRB2 P07550 1/20 0.70
CHRM2 P08172 1/20 0.70
CHRM4 P08173 1/20 0.70
ABCB1 P08183 1/20 0.70
HTR1A P08908 1/20 0.70
CHRM5 P08912 1/20 0.70
ADRA2A P08913 1/20 0.70
CHRM1 P11229 1/20 0.70
DRD2 P14416 1/20 0.70
ADRA2B P18089 1/20 0.70
ADRA2C P18825 1/20 0.70
CHRM3 P20309 1/20 0.70
DRD1 P21728 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4460572 0.89 HRH1 (0.82) PTAFRHRH1SLC6A15FNTAFNTB
SCHEMBL31384618 0.89 HRH1 (0.82) PTAFRHRH1SLC6A15FNTAFNTB
SCHEMBL29626502 0.89 HRH1 (0.82) PTAFRHRH1SLC6A15FNTAFNTB
SCHEMBL20777155 0.88 PTAFR (0.75) PTAFRHRH1SLC6A15FNTAFNTB
SCHEMBL3367280 0.86 SLC6A15 (0.82) PTAFRHRH1SLC6A15FNTAFNTB
SCHEMBL31305643 0.86 PTAFR (1.00) PTAFRHRH1SLC6A15FNTAFNTB
SCHEMBL8876967 0.86 PTAFR (1.00) PTAFRHRH1SLC6A15FNTAFNTB
SCHEMBL8878295 0.85 SLC6A15 (0.80) PTAFRHRH1SLC6A15FNTAFNTB
Sch-37370 SCHEMBL3071641 0.85 PTAFR (1.00) PTAFRHRH1SLC6A15FNTAFNTB
SCHEMBL2738854 0.85 PTAFR (0.71) PTAFRHRH1SLC6A15FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8187630-B2 Extended release oral dosage composition SCHERING-PLOUGH CORPORATION (US) 2012-05-29 US disclosed
US-8187630-B2 Extended release oral dosage composition SCHERING-PLOUGH CORPORATION (US) 2012-05-29 US disclosed
US-20100021542-A1 EXTENDED RELEASE ORAL DOSAGE COMPOSITION SCHERING CORPORATION (US) 2010-01-28 US disclosed
US-20100021542-A1 EXTENDED RELEASE ORAL DOSAGE COMPOSITION SCHERING CORPORATION (US) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021542-A1 EXTENDED RELEASE ORAL DOSAGE COMPOSITION HRH2, QDPR, HRH1 PTAFR 1672/4885HRH1 3/4885SLC6A15 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.